Evidence map›Paper›PMID 39424749›Full record

ArticleBiotechnology letters2024

Recombinant expression, downstream optimization, and therapeutic evaluation of recombinant human interleukin-37 for cancer therapy.

Zaheer Abbas, Samia Afzal, Nao Akusa Fujimura, Muhammad Akram, Saad Tahir, Kausar Malik, Nadeem Ahmed

Abstract read
PubMed Publisher
In one paragraph

Article in Biotechnology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zaheer AbbasCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
Samia AfzalCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
Nao Akusa FujimuraCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
Muhammad AkramCentre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
Saad TahirCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
Kausar MalikCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan.
Nadeem AhmedCentre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan. nadeem.ahmed@cemb.edu.pk.ORCID http://orcid.org/0000-0003-3413-9417

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-37 is a cytokine with potent immunosuppressive properties that has been shown to have potential to treat autoimmune and chronic inflammatory diseases, as well as certain types of cancer. IL-37 is a 19 kDa protein which interacts with proteins in receptor-dependent and receptor-independent pathways. The expression of the IL-37 protein cloned into the pET-28a vector was optimized in Rosetta 2(DE3) after comparing its expression with Rosetta-gami 2(DE3) and Rosetta 2(DE3) pLysS, which was then used for the large-scale production of IL-37. IMAC purification of IL-37 yielded > 97% pure 0.9 mg/mL protein from auto-induced fermentation. The IC

Indexed as

Interleukin-1NeoplasmsRecombinant ProteinsAntineoplastic AgentsCell Line, TumorCell ProliferationCloning, MolecularDoxorubicinEscherichia coliGene ExpressionHumansAntineoplastic AgentsDoxorubicinIL37 protein, humanInterleukin-1Recombinant ProteinsCancer therapyComputational analysisIMAC purificationMedia optimizationRecombinant IL-37Soluble expression

Identifiers

PMID39424749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.